- Home
- TRIP vs IDYA Comparison
TRIP vs IDYA Comparison
Compare TRIP & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRIP
- IDYA
- Stock Information
- Founded
- TRIP 2000
- IDYA 2015
- Country
- TRIP United States
- IDYA United States
- Employees
- TRIP N/A
- IDYA N/A
- Industry
- TRIP Computer Software: Programming Data Processing
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- TRIP Technology
- IDYA Health Care
- Exchange
- TRIP Nasdaq
- IDYA Nasdaq
- Market Cap
- TRIP 1.6B
- IDYA 1.5B
- IPO Year
- TRIP 2011
- IDYA 2019
- Fundamental
- Price
- TRIP $14.94
- IDYA $18.18
- Analyst Decision
- TRIP Hold
- IDYA Strong Buy
- Analyst Count
- TRIP 14
- IDYA 13
- Target Price
- TRIP $17.50
- IDYA $53.58
- AVG Volume (30 Days)
- TRIP 2.5M
- IDYA 1.5M
- Earning Date
- TRIP 05-07-2025
- IDYA 05-06-2025
- Dividend Yield
- TRIP N/A
- IDYA N/A
- EPS Growth
- TRIP 114.07
- IDYA N/A
- EPS
- TRIP 0.37
- IDYA N/A
- Revenue
- TRIP $1,838,000,000.00
- IDYA $7,000,000.00
- Revenue This Year
- TRIP $6.27
- IDYA $121.20
- Revenue Next Year
- TRIP $7.64
- IDYA $302.20
- P/E Ratio
- TRIP $38.73
- IDYA N/A
- Revenue Growth
- TRIP 1.44
- IDYA N/A
- 52 Week Low
- TRIP $10.43
- IDYA $13.45
- 52 Week High
- TRIP $27.63
- IDYA $44.42
- Technical
- Relative Strength Index (RSI)
- TRIP 68.08
- IDYA 48.15
- Support Level
- TRIP $12.46
- IDYA $16.82
- Resistance Level
- TRIP $13.06
- IDYA $21.43
- Average True Range (ATR)
- TRIP 0.52
- IDYA 1.19
- MACD
- TRIP 0.35
- IDYA -0.06
- Stochastic Oscillator
- TRIP 94.64
- IDYA 29.65
About TRIP TripAdvisor Inc.
Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on several million accommodations, restaurants, experiences, airlines, and cruises. In 2024, 52% of revenue came from the company's core Brand Tripadvisor segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 46% of sales in 2024, and TheFork, its dining brand, represented 10% of revenue (about 8% of sales were intersegment, which are eliminated from consolidated revenue).
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.